within Pharmacolibrary.Drugs.ATC.A;

model A02BB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02BB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Enprostil is a synthetic prostaglandin E2 analogue that acts as a gastroprotective agent, primarily improving gastric mucosal defense and inhibiting gastric acid secretion. It was developed for the treatment and prevention of gastric and duodenal ulcers. Enprostil is not widely approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adult subjects, as no original clinical PK data are available in the literature.</p><h4>References</h4><ol><li><p>Kohno, M, et al., &amp; Chaplin, M (1989). Metabolic fate of the new anti-ulcer drug enprostil in animals. 3rd communication: tissue accumulation after consecutive oral administration of [3H]-enprostil in rats. <i>Arzneimittel-Forschung</i> 39(3) 350–356. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2502988/\">https://pubmed.ncbi.nlm.nih.gov/2502988</a></p></li><li><p>Nauck, MA, et al., &amp; Schmiegel, W (1997). Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. <i>Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association</i> 105(4) 187–195. DOI:<a href=\"https://doi.org/10.1055/s-0029-1211750\">10.1055/s-0029-1211750</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9285204/\">https://pubmed.ncbi.nlm.nih.gov/9285204</a></p></li><li><p>Vanhanen, H, &amp; Miettinen, TA (1995). Enprostil impairs cholesterol and fat absorption. <i>Scandinavian journal of gastroenterology</i> 30(1) 33–37. DOI:<a href=\"https://doi.org/10.3109/00365529509093232\">10.3109/00365529509093232</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7701247/\">https://pubmed.ncbi.nlm.nih.gov/7701247</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02BB02;
